UK to become global hub for contract manufacturing services
Lakeside North Harbour, Portsmouth, UK; July 28, 2022: Together with numerous guests from politics, economics, life sciences and medical diagnostics, SCIENION the precision liquid handling specialist and part of bioconvergence powerhouse BICO, today celebrated the opening of new state of the art facilities in Portsmouth. More than 1,000 square meters will enable SCIENION UK to run customer R&D projects including single cell applications. The new location provides ISO5 clean room facilities for contract manufacturing services to address the rapidly growing UK and worldwide customer base.
SCIENION’s UK customer base has significantly expanded over the last 15 years. In order to interact closer with its customer base, SCIENION UK Ltd. was founded in Chichester in 2019 and led to the expansion to new facilities in Portsmouth. SCIENION UK is now able to promote and provide more extensive services and opportunities for collaborations with its UK customers.
Dr Holger Eickhoff, founder and CEO of SCIENION GmbH and BICO SVP & Business Area Bioautomation Director, said: “Despite all Brexit and Covid challenges in recent years we are proud that we could support our important UK customers with our products, services and technologies which are key in modern diagnostic test manufacturing. Having examined a number of possible options, SCIENION is convinced that the new global hub for contract manufacturing in Portsmouth is the best possible for the Group, and will create the highest value for all Stakeholders.”
Dr Andrew Sweet, Managing Director of SCIENION UK, Ltd was especially glad to welcome The Lord Mayor of Portsmouth and the Lady Mayoress, Councillor Canon Dr Hugh Mason and Miss Marie Costa and Penny Mordaunt, Member of Parliament, along with guests from the life sciences and medical diagnostics sectors. He said: “It is an honor and great pleasure for us to jointly celebrate with you the opening of our new facilities. Here at Lakeside North Harbour, we now have the facilities, personnel and equipment to enable, inspire and educate customers to develop their research projects through to full scale manufacturing. Further to be able to participate in the extraordinary innovations in cancer research being advanced by UK pharmaceutical and academic institutions.”
Penny Mourdant, Member of Parliament for Portsmouth North, said: “It is exciting to see SCIENION bring their technologies, services, and contract manufacturing capabilities to Portsmouth. As a Government, we strongly support the sector and have a bold life sciences vision to work with companies like SCIENION to bring innovative solutions to the healthcare challenges of our time.”
As the UK hub for the BICO group, SCIENION and sister companies will be utilizing the new premises to showcase their capabilities and expertise in the bioautomation, bioprinting and biosciences arenas, forging key collaborations with scientists, academics and industrial partners.
Founded in 2001, SCIENION is a renowned specialist in ultra-low volume precision liquid handling in the pico-liter to micro-liter range, enabling applications from research to high-throughput production of assays in diagnostics and life sciences. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION is an ISO 9001:2015 certified complete solution provider offering a unique portfolio of automated precision dispensing systems, readers, consumables, assay development and contract manufacturing services. The company operates from two sites in Germany, Berlin and Dortmund, and has subsidiaries in Phoenix, Arizona (USA), Portsmouth (UK), and Lyon (France). The French subsidiary Cellenion offers solutions for single cell analyses, e.g. with the single cell dispenser cellenONE and products such as cellenCHIP and proteoCHIP for omics-based applications.
SCIENION is part of BICO, the leading bio convergence company in the world that provides technologies, products and services to create the future of health.
Founded in 2016, BICO (formerly CELLINK) is the world’s leading bioconvergence company,with three business areas: Biosciences, Bioautomation, and Bioprinting. BICO reduces the organ shortage and speeds up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry.
Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development in 3D, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people’s health and lives.
Our products are trusted by more than 3,500 laboratories, including the top 20 pharmaceutical companies. We have more than 32,000 instruments in the field in over 65 countries and have been cited in over 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com.
Phone: +49 (0)30 – 6392 1700
Phone +49 (0)30 – 6120 1081
Mobile +49 (0)174 3017754
Email [email protected]